Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

NCT ID: NCT05008575

Last Updated: 2022-01-12

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 27 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-12-23
• Study Completion Date: 2023-12-01

Brief Summary

CAR technology has been used in T cell therapy and gets great success in treating hematological diseases. Following models of CAR T cells, CAR NK cell therapy has been one hot point. For myeloid malignancies, CD33 is widely expressed. Targeting CD33 surface antigens by CAR NK cells provides an off-the-shelf immune cell therapy.

Conditions

Leukemia, Myeloid, Acute

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

antiCD33 CAR NK cells

After preconditioning with chemotherapy, the antiCD33 CAR NK cells will be evaluated

Group Type: EXPERIMENTAL

anti-CD33 CAR NK cells

Intervention Type: BIOLOGICAL

6×10\^8, 12×10\^8, 18×10\^8/KG Treatment follows a lymphodepletion

Fludarabine

Intervention Type: DRUG

recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.

Cytoxan

Intervention Type: DRUG

recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.

Interventions

anti-CD33 CAR NK cells

6×10\^8, 12×10\^8, 18×10\^8/KG Treatment follows a lymphodepletion

Intervention Type: BIOLOGICAL

Fludarabine

recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.

Intervention Type: DRUG

Cytoxan

recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. ECOG performance status score ≤ 2.

2. Life expectancy ≥ 12 weeks from the time of enrollment.

3. Disease status at the time of enrollment: -Patients with AML (except M3) who have not achieved complete remission after standard chemotherapy regimens; -Not suitable or unconditional for allogeneic hematopoietic stem cell transplantation; -Patients with recurrent acute myeloid leukemia after autologous hematopoietic stem cell transplantation without active graft-versus-host disease (GVHD).

4. CD33 expression must be detected on greater than 50% of the malignant cells by immunohistochemistry or greater than 80% by flow cytometry.

5. Adequate main organ function as assessed by the following laboratory requirements: creatinine ≤ 2.5 × upper limit of normal, cardiac ejection fraction ≥ 40%, oxygen saturation ≥ 90%, total bilirubin ≤ 3 × upper limit of normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal, Hgb≥80g/L.

6. Without history of accepting anti-cancer therapy, including chemotherapy, radiotherapy, immunotherapy (immune suppressive drugs or corticosteroid treatment) within 4 weeks of screening.

7. Women of child-bearing age must have evidence of negative pregnancy test.

8. Subjects of reproductive potential must agree to use acceptable birth control methods within 1 year after treatment, as described in protocol.

9. After discussion by the expert group, the patient's condition was analyzed and combined with the general physical condition of the patient, the benefit of participating in the clinical trial was greater than the risk.

10. All participants must have the ability to understand and willingness to sign a written informed consent.

Exclusion Criteria

1. Diagnosis of acute promyelocytic leukemia (APL M3): t(15;17)(q22;q12); (promyelocytic leukemia [PML]/retinoic acid receptor [RAR] alpha [a]) and variants excluded.

2. Active acute or chronic GVHD or requirement of immunosuppressant medications for GVHD within 4 weeks of enrollment.

3. Have been diagnosed with or treated other malignant tumors other than AML within 5 years before screening, except for the following conditions: participants with adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer; or received radical treatment Local prostate cancer, ductal carcinoma in situ.

4. There are serious systemic diseases: New York Heart Association (NYHA) stage III or IV congestive heart failure; cerebrovascular accident or myocardial infarction or hemodynamic instability caused by arrhythmia within 6 months before signing the informed consent; impaired cardiac function (LVEF<50%) assessed by echocardiographic scan.

5. Sever illness or medical condition, which would not permit the patient to be managed according to the protocol, including active uncontrolled infection.

6. Pregnant or lactating women.

7. Subjects with radiologically-detected CNS chloromas or CNS 3 disease (presence of ≥ 5/μL white blood cells (WBCs) in cerebral spinal fluid (CSF) and cytospin positive for blasts [in the absence of a traumatic lumbar puncture] and/or clinical signs of CNS leukemia such as a cranial nerve palsy from active disease). Subjects with adequately treated CNS leukemia are eligible.

8. Human immunodeficiency virus (HIV) seropositivity; hepatitis B surface antigen is positive or HBV DNA is higher than the detection limit of the analysis method; hepatitis C antibody is positive or HCV RNA is higher than the detection limit of the analysis method; syphilis antibody and syphilis rapid plasma reagin are positive; CMV DNA is positive.

9. Patients who suffer from allergies for any cytokines or antibodies.

10. Contraindications for fludarabine or cyclophosphamide treatment.

11. Receiving corticosteroids at >20 mg daily prednisone dose or equivalent.

12. Drug abuse and addiction.

13. History of mental disorders.

14. Other patients that researchers considered unsuitable for inclusion.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Xinqiao Hospital of Chongqing

OTHER

Sponsor Role: lead

Responsible Party

Xi Zhang, MD

chef of hemotology department

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

xi zhang, MD/PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Hematology, Xinqiao Hospital

Locations

Department of Hematology, Xinqiao Hospital

Chongqing, Chongqing Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Xi zhang, MD/PhD

Role: CONTACT

zhangxxi@sina.com

13808310064 ext. +86

ruihao huang, MD

Role: CONTACT

1169731117@qq.com

18984398751 ext. +86

Facility Contacts

Xi Zhang, MD/PhD

Role: primary

zhangxxi@sina.com

13808310064 ext. +86

Ruihao Huang, PhD candidate

Role: backup

1169731117@qq.com

18984398751 ext. +86

References

Huang R, Wang X, Yan H, Tan X, Ma Y, Wang M, Han X, Liu J, Gao L, Gao L, Jing G, Zhang C, Wen Q, Zhang X. Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML: preclinical evaluation and phase I trial. Exp Hematol Oncol. 2025 Jan 2;14(1):1. doi: 10.1186/s40164-024-00592-6.

Reference Type: DERIVED

PMID: 39748428 (View on PubMed)

Other Identifiers

CD33 CAR NK-AML

Identifier Type: -

Identifier Source: org_study_id